Physician profile

Pradeep S Parihar

Family Medicine · Allen, TX

NPI 1316033418

$4,117.26

in general payments reported to CMS, 2019-2025

43 companies · $1,148 in 2025

The $1,148 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).

See the full distribution for Family Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,691.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $521.99 2020-2025 Farxiga, Breztri, Airsupra
Lilly USA, LLC $510.11 2019-2025 Mounjaro, Jardiance, Zepbound
Abbott Laboratories $404.21 2019-2025 Freestyle Libre 3, Proclaim
Boehringer Ingelheim Pharmaceuticals, INC. $308.72 2020-2025 Jardiance
Novo Nordisk INC $283.97 2020-2025 Ozempic, Rybelsus, Wegovy
Phathom Pharmaceuticals, INC. $215.08 2024-2025 Voquezna
Abbvie INC. $201.83 2021-2025
Merck Sharp & Dohme LLC $177.46 2020-2022
Kowa Pharmaceuticals America, INC. $154.58 2025 Zoryve
Glaxosmithkline, LLC. $140.95 2024-2025 Trelegy Ellipta, Arexvy, Shingrix
Bayer Healthcare Pharmaceuticals INC. $121.38 2024-2025
Janssen Pharmaceuticals, INC $103.17 2023-2024 Spravato
Dexcom, INC. $96.99 2024-2025 Dexcom G6 Transmitter
Vivus LLC $84.88 2025 Pancreaze, Qsymia
Amgen INC. $64.67 2023-2025 Repatha, Otezla, Evenity
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Aimmune Therapeutics, INC. $58.74 2025 Zenpep
Idorsia Pharmaceuticals US INC $55.79 2023 Quviviq
Medtronic, INC. $54.15 2022
Pfizer INC. $49.73 2024-2025
Novartis Pharmaceuticals Corporation $34.34 2022
Genentech USA, INC. $34.27 2021
Exact Sciences Corporation $29.92 2024-2025 Cologuard Collection Kit
Medtronic USA, INC. $28.16 2019-2020
Dermira, INC. $27.69 2019
Redhill Biopharma INC. $27.46 2020
Acelrx Pharmaceuticals, INC. $24.70 2023 Dsuvia
Eisai INC. $23.02 2021
Corcept Therapeutics $22.36 2025 Korlym
Braintree Laboratories, INC. $21.91 2022
Si-Bone, INC. $21.86 2022
Takeda Pharmaceuticals U.S.A., INC. $20.80 2021
Nestle Healthcare Nutrition INC. $19.83 2023
Radius Health, INC. $19.79 2025 Tymlos
Cardiovascular Systems INC. $18.66 2020
Esperion Therapeutics, INC. $17.08 2021
Ultragenyx Pharmaceutical INC. $16.76 2022
Bioventus LLC $16.55 2019
Biohaven Pharmaceuticals, INC. $15.86 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $15.74 2024 Xifaxan
Supernus Pharmaceuticals, INC. $14.97 2023 Qelbree
Renalytix Ai, INC. $13.80 2025 Kidneyintelx Blood Collection Convenience Kit
Evofem Biosciences, INC. $12.12 2022
Dynavax Technologies Corporation $11.21 2023 Heplisav-B

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Pradeep S Parihar

$4,117.26

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $1,148 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/969738/pradeep-s-parihar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.